AbBC Therapies to Present Innovative Treatments at 45th Goldman Sachs Healthcare Conference

AbBC Therapies, Inc., known for its advancements in antibody-biological conjugates (AbBCs), has announced its attendance at the 45th Annual Goldman Sachs Global Healthcare Conference, which will be held at the Loews Miami Beach Hotel in Miami Beach, Fla.

Ian Estepan, the Executive Chairman of AbBC Therapies, is scheduled to present on June 11, 2024, at 4:00 p.m. ET. His presentation will focus on AbBC's unique targeted granzyme B immunotherapy (TGI) platform, a novel solution designed to address the shortcomings of current antibody drug conjugates (ADCs) and immunotherapies. This innovative platform aims to provide targeted treatments for a wide array of cancers and other serious diseases.

"We are thrilled to participate in the Goldman Sachs Global Healthcare Conference and to demonstrate how AbBC technology integrates the advantages of ADCs and immunotherapies into a single molecule," commented Mr. Estepan. "Our TGI platform has the potential to significantly enhance treatment by offering better efficacy and fewer side effects for patients battling cancer and other severe illnesses."

The presentation will cover several key aspects, including:

1. The design and structure of the TGI platform,
2. Preclinical data demonstrating the efficacy and safety of AbBC’s TGI platform,
3. The strategy for development and value creation.

About AbBC Therapies

AbBC Therapies is at the forefront of developing a cutting-edge targeted therapeutic platform that merges the tumor-targeting abilities of ADCs with the granzyme B killing mechanism found in immunotherapies, creating a single hybrid molecule. This proprietary platform is specifically engineered to overcome the limitations of existing ADCs and immunotherapies, enabling targeted therapies with enhanced effectiveness and fewer side effects.

The TGI platform includes a pipeline comprising seven products under development, targeting various indications in ophthalmology and broad oncology. AbBC Therapies is dedicated to advancing its pipeline with the objective of transforming the treatment landscape for patients with cancer and other life-threatening diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!